reports
VINCI: Disclosure of transactions in on shares from November 17th to N...
VINCI: Disclosure of transactions in on shares from November 17th to November 21st,2025 Nanterre, November 24th, 2025 Disclosure of transactions in on shares from November 17th to November 21st,2025 Within the framework of the authorization granted by the General Meeting of VINCI SA of April 17th, 2025, to trade in its shares and in accordance with the regulations relating to share buybacks, VINCI SA (LEI:213800WFQ334R8UXUG83) declares the purchases of treasury shares below (FR0000125486), carried out from November 17th to November 21st,2025: I - Aggregate prese...
VINCI : Déclaration des transactions sur actions propres Du 17 Novembr...
VINCI : Déclaration des transactions sur actions propres Du 17 Novembre au 21 Novembre 2025 Nanterre, le 24 novembre 2025 Déclaration des transactions sur actions propres Du 17 Novembre au 21 Novembre 2025 Dans le cadre de l’autorisation consentie par l’Assemblée générale de VINCI SA du 17 avril 2025 pour opérer sur ses actions et conformément à la réglementation relative aux rachats d’action, VINCI SA (LEI: 213800WFQ334R8UXUG83) déclare ci-après les achats d’actions propres (FR0000125486) réalisés du 17 Novembre au 21 Novembre 2025 : I - Présentation agrégée par jour et par marché Nom...
Press Release: Sanofi and Regeneron’s Dupixent approved as the first t...
Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placeboIn the EU, there are approximately 270,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite standard-of-care antihistamine treatmentDupixent, which i...
Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a ...
Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé comme étant le premier médicament ciblé dans l’UE depuis plus de dix ans contre l’urticaire chronique spontanée Dupixent, développé par Sanofi et Regeneron, a été approuvé comme étant le premier médicament ciblé dans l’UE depuis plus de dix ans contre l’urticaire chronique spontanée Approval based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placeboIn the EU, there are approximately 270,000 adults and adolescents aged 12 years and older living with CSU wh...
- Research Department
IBERIAN DAILY 20 NOVEMBER (ANÁLISIS BANCO SABADELL)
NEWS SUMMARY: N/A. Market relief European markets ended with gains yesterday after several sessions of corrections, also underpinned by rumours about a possible peace offer to Ukraine agreed between the US and Russia. Amid doubts surrounding AI the attention turned towards Nvidia’s results release after yesterday’s closing bell, which beat expectations and raised its 4Q guidance. In the STOXX 600, all the sectors except Telecoms, Utilities and Energy closed with gains, led by Media and Travel&L...
Disclosure of transactions in on shares from November 10th to Novembe...
Disclosure of transactions in on shares from November 10th to November 14th,2025 Nanterre, November 18th, 2025 Disclosure of transactions in on shares from November 10th to November 14th,2025 Within the framework of the authorization granted by the General Meeting of VINCI SA of April 17th, 2025, to trade in its shares and in accordance with the regulations relating to share buybacks, VINCI SA (LEI:213800WFQ334R8UXUG83) declares the purchases of treasury shares below (FR0000125486), carried out from November 10th to November 14th,2025: I - Aggregate presentatio...
Déclaration des transactions sur actions propres du 10 novembre au 14 ...
Déclaration des transactions sur actions propres du 10 novembre au 14 novembre 2025 Nanterre, le 18 novembre 2025 Déclaration des transactions sur actions propres Du 10 novembre au 14 novembre 2025 Dans le cadre de l’autorisation consentie par l’Assemblée générale de VINCI SA du 17 avril 2025 pour opérer sur ses actions et conformément à la réglementation relative aux rachats d’action, VINCI SA (LEI: 213800WFQ334R8UXUG83) déclare ci-après les achats d’actions propres (FR0000125486) réalisés du 10 Novembre au 14 Novembre 2025 : I - Présentation agrégée par jour et par marché Nom de l'ém...
VINCI Autoroutes and VINCI Airports traffic in October 2025
VINCI Autoroutes and VINCI Airports traffic in October 2025 Nanterre, 18 November 2025 VINCI Autoroutes and VINCI Airports traffic in October 2025 I- Change in VINCI Autoroutes’ intercity networks traffic OctoberYTD at the end of October (10 months) % change 2025/2024% change 2025/2024VINCI Autoroutes+1.9%+1.4% Light vehicles+2.2%+1.6% Heavy vehicles−0.2%+0.7% In October, traffic at VINCI Autoroutes recorded a solid growth (+1.9%), driven by light vehicles. This confirms the increase since the beginning of the year to +1.4%, including +1.6% for light vehicles and +0.7% for heavy...
Trafics de VINCI Autoroutes et de VINCI Airports en octobre 2025
Trafics de VINCI Autoroutes et de VINCI Airports en octobre 2025 Nanterre, le 18 novembre 2025 Trafics de VINCI Autoroutes et de VINCI Airports en octobre 2025 I- Évolution du trafic des réseaux interurbains de VINCI Autoroutes OctobreCumul à fin octobre(10 mois) % Variation 2025/2024% Variation 2025/2024VINCI Autoroutes+1,9 %+1,4 % Véhicules légers+2,2 %+1,6 % Poids lourds−0,2 %+0,7 % En octobre, le trafic de VINCI Autoroutes affiche une solide progression (+1,9 %), tirée par les véhicules légers. Celle-ci conforte la hausse depuis le début de l’année à +1,4 %, dont +1,6 % po...
- Luis Arredondo
- Bruno Cavalier
- Maissa Keskes
- Marc Lavaud
- Stephane Houri
- Thomas Zlowodzki
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
ALV ALLIANZ SE
NOKIA NOKIA OYJ
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
WPP WPP PLC
01913 PRADA S.P.A.
MONC MONCLER SPA
ACS ACTIVIDADES DE CONSTRUCCION Y SERVICIOS SA
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
MERLIN MERLIN PROPERTIES SOCIMI S.A.
SAP SAP SE
SIGN SIG COMBIBLOC GROUP LTD
ENR SIEMENS ENERGY AG
ANE CORPORACION ACCIONA ENERGIAS RENOVABLES SA
ZGN ERMENEGILDO ZEGNA NV
H2O HIDROELECTRICA S.A.
- Bruno Cavalier
- Maissa Keskes
- Marc Lavaud
- Stephane Houri
- Thomas Zlowodzki
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
ALV ALLIANZ SE
NOKIA NOKIA OYJ
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
WPP WPP PLC
01913 PRADA S.P.A.
MONC MONCLER SPA
ACS ACTIVIDADES DE CONSTRUCCION Y SERVICIOS SA
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
MERLIN MERLIN PROPERTIES SOCIMI S.A.
SAP SAP SE
SIGN SIG COMBIBLOC GROUP LTD
ENR SIEMENS ENERGY AG
ANE CORPORACION ACCIONA ENERGIAS RENOVABLES SA
ZGN ERMENEGILDO ZEGNA NV
H2O HIDROELECTRICA S.A.
- Ana Arjona-Martinez
- Research Department
IBERIAN DAILY 17 NOVEMBER + 3Q’25 RESULTS. PREVIEWS (ANÁLISIS BANCO SA...
NEWS SUMMARY: ACS, TELEFÓNICA. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 3Q’25 results to be released over the coming days in Spain. Fear of AI bubble brings volatility Following the record highs reached last week thanks to the hope of an end to the shutdown in the US and the solid business results, stock markets reeled in part of the gains due to the concerns of a bubble...
- Research Department
INFORME DIARIO 17 NOVIEMBRE + RDOS. ESPAÑA 3T’25. PREVIEWS (ANÁLISIS B...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ACS, TELEFÓNICA. EUROPA: AIRBUS, PROSUS. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 3T’25 que se publicarán en España y Europa en los próximos días. El temor a una burbuja en la IA genera volatilidad en las bolsas Tras los máximos históricos alcanzados en la semana gracias a la esperanza de una resoluci...
- Luis Arredondo
ACS: 3Q’25 RESULTS (ANÁLISIS BANCO SABADELL)
3Q'25 vs. 3Q'24 Results Sales: € 12.65 Bn (15.4% vs. 17.6% BS(e) and 9.1% consensus); EBITDA: € 783 M (50.0% vs. 54.2% BS(e) and 48.7% consensus); EBIT: € 555 M (104.0% vs. 98.5% BS(e) and 49.3% consensus); Net Profit: € 205 M (8.5% vs. 6.3% BS(e) and 8.7% consensus); 9M'25 vs. 9M'24 Results Sales: € 36.75 Bn (23.7% vs. 24.5% BS(e) and 21.4% consensus); EBITDA: € 2.22 Bn (32.0% vs. 33.4% BS(e) and 31.6% consensus); EBIT: € 1.5 Bn (38.7% vs. 37.3% BS(e) and 33.5% consensus); Net Profit: € 655 M...
Press Release: Sanofi’s Teizeild recommended for EU approval by the CH...
Press Release: Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes Recommendation based on the TN-10 study, demonstrating Teizeild’s ability to delay the onset of stage 3 type 1 diabetes (T1D), compared to placebo, in adults and children with stage 2 T1DIf approved, Teizeild would become the first disease-modifying T1D therapy in the EU Paris, November 14, 2025. The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human ...
Communiqué de presse : Teizeild, un médicament Sanofi, a reçu l’approb...
Communiqué de presse : Teizeild, un médicament Sanofi, a reçu l’approbation du CHMP pour une autorisation de mise sur le marché dans l’UE chez les patients atteints de diabète de type 1 de stade 2 Teizeild, un médicament Sanofi, a reçu l’approbation du CHMP pour une autorisation de mise sur le marché dans l’UE chez les patients atteints de diabète de type 1 de stade 2 La recommandation s’appuie sur l’étude TN-10, qui démontre la capacité du Teizeild à retarder l’apparition du stade 3 du diabète de type 1 (DT1), par rapport au placebo, chez les adultes et les enfants atteints de DT1 de stad...
Sanofi: 1 director
A director at Sanofi bought 207 shares at 7,909p and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Clos...
- Baptiste Salaville
- Chaima Ferrandon
- Charlotte Vaisse
- Sven Edelfelt
LOGN LOGITECH INTERNATIONAL S.A.
FP TOTAL SE
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
RNO RENAULT SA
G1A GEA GROUP AG
PUM PUMA SE
FGR EIFFAGE SA
G ASSICURAZIONI GENERALI S.P.A.
ALO ALSTOM SA
ENI ENI S.P.A.
ENEL ENEL SPA
SY1 SYMRISE AG
REP REPSOL SA
ANA ACCIONA SA
BC8 BECHTLE AG
ACS ACTIVIDADES DE CONSTRUCCION Y SERVICIOS SA
STR STRABAG SE
MERLIN MERLIN PROPERTIES SOCIMI S.A.
SIE SIEMENS AG
BP. BP P.L.C.
REY REPLY S.P.A.
LAND LAND SECURITIES GROUP PLC
SAB BANCO DE SABADELL SA
ENR SIEMENS ENERGY AG
ANE CORPORACION ACCIONA ENERGIAS RENOVABLES SA
SHEL SHELL PLC
CVC CVC CAPITAL PARTNERS PLC
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.